Metabolic Liver Disease and Cancer Transition: Central Role of the FBP1 Regulatory Axis

References

[1] L. Gu, Y. Zhu, S. P. Nandi, et al., “FBP1 controls Liver Cancer Evolution From Senescent MASH Hepatocytes,” Nature 637, no. 8045 (2025): 461-469.

[2] X. Wang, L. Zhang, and B. Dong, “Molecular Mechanisms in MASLD/MASH Related HCC,” Hepatology (2024): 10.1097.

[3] M. Karin and J. Y. Kim, “MASH as an Emerging Cause of Hepatocellular Carcinoma: Current Knowledge and Future Perspectives,” Molecular Oncology 19, no. 2 (2025): 275-294.

[4] W. Wang, K. Xu, M. Shang, et al., “The Biological Mechanism and Emerging Therapeutic Interventions of Liver Aging,” International Journal of Biological Sciences 20, no. 1 (2024): 280.

[5] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.